Naomi Hunder - Feb 1, 2022 Form 4 Insider Report for Silverback Therapeutics, Inc. (SPRY)

Role
Chief Medical Officer
Signature
/s/ Jeffrey C. Pepe, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/2/2022, 04:18 PM
Next filing
May 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Award $0 +11.3K $0.00 11.3K Feb 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (right to buy) Award $0 +67.5K $0.00 67.5K Feb 1, 2022 Common Stock 67.5K $4.85 Direct F2
transaction SPRY Stock Option (right to buy) Award $0 +42.8K $0.00 42.8K Feb 1, 2022 Common Stock 42.8K $4.85 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock.
F2 The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022.
F3 25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years.